journal
Journals Clinical Lymphoma, Myeloma & L...

Clinical Lymphoma, Myeloma & Leukemia

https://read.qxmd.com/read/38403505/azacitidine-post-transplant-maintenance-improves-disease-progression-in-high-risk-acute-myeloid-leukemia-and-myelodysplastic-syndrome
#1
JOURNAL ARTICLE
Oren Pasvolsky, Rima M Saliba, Uday R Popat, Amin Alousi, Rohtesh Mehta, Jason Yeh, Gheath Al-Atrash, Masood Adeel, Jeremy Ramdial, David Marin, Gabriela Rondon, Partow Kebriaei, Richard Champlin, Naval Daver, Courtney Dinardo, Nicholas J Short, Elizabeth J Shpall, Betül Oran
BACKGROUND: Maintenance after allogeneic hematopoietic cell transplantation (alloHCT) with hypomethylating agents has yielded conflicting results. MATERIALS AND METHODS: We conducted a single center retrospective matched-control analysis with the study group (5-azacitidine [AZA] group) including adults with FLT3-negative acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who received post-transplant AZA maintenance off clinical trial (n = 93). A matched control group was comprised of contemporaneous AML/MDS patients who did not receive any maintenance (n = 357)...
February 3, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38369437/optimizing-the-car-t-cell-therapy-experience-in-multiple-myeloma-clinical-pearls-from-an-expert-roundtable
#2
JOURNAL ARTICLE
Sikander Ailawadhi, Leyla Shune, Sandy W Wong, Yi Lin, Krina Patel, Sundar Jagannath
Chimeric antigen receptor T-cell (CAR-T) therapies offer substantial advancement in the treatment of multiple myeloma (MM). However, the CAR-T therapy process involves complex decision-making that is informed by many variables. This review aims to provide an overview of the patient selection and administration process for CAR-T therapy for MM from the perspective of experienced healthcare providers (HCPs), including considerations for each step in the CAR-T therapy process. Referring HCPs should initiate conversations with HCPs at CAR-T capable centers earlier in the treatment journey, even before patients are eligible for CAR-T therapy, particularly for patients from underserved populations and patients with high-risk disease, to ensure adequate time for logistical planning and patient education...
February 1, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38369436/the-italian-multicentric-randomized-optkima-trial-on-fixed-vs-progressive-intermittent-tki-therapy-in-cml-elderly-patients-3-years-of-molecular-response-and-quality-of-life-monitoring-after-completing-the-treatment-plan
#3
JOURNAL ARTICLE
Michele Malagola, Alessandra Iurlo, Cristina Bucelli, Elisabetta Abruzzese, Massimiliano Bonifacio, Fabio Stagno, Gianni Binotto, Marienlla D'Adda, Monia Lunghi, Monica Crugnola, Maria Luisa Ferrari, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Roberto Massimo Lemoli, Rosaria Sancetta, Maria Rosaria Coppi, Maria Teresa Corsetti, Marco De Gobbi, Atelda Romano, Mario Tiribelli, Antonella Russo Rossi, Sabina Russo, Marzia Defina, Mirko Farina, Simona Bernardi, Giulia Butturini, Simone Pellizzeri, Aldo Maria Roccaro, Domenico Russo
BACKGROUND: Intermittent treatment with tyrosine kinase inhibitors (TKIs) is an option for elderly chronic myeloid leukemia (CML) patients who are often candidates for life-long treatment. MATERIALS AND METHODS: The Italian phase III multicentric randomized Optimize TKIs Multiple Approaches (OPTkIMA) study aimed to evaluate if a progressive de-escalation of TKIs is able to maintain the molecular remission (MR)3.0 and to improve Health-Related Quality of Life (HRQoL) in CML elderly patients...
January 25, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38365528/a-comparison-of-3-year-follow-up-of-zuma-5-axicabtagene-ciloleucel-with-scholar-5-in-relapsed-refractory-follicular-lymphoma
#4
EDITORIAL
Paola Ghione, M Lia Palomba, Markqayne D Ray, Eve H Limbrick-Oldfield, Jessica Owen, Steve Kanters, Sabela Bobillo, Maria Teresa Ribiero, Caron A Jacobson, Sattva S Neelapu, Herve Ghesquieres, Myrna Nahas, Sara Beygi, Anik R Patel, John G Gribben
In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory follicular lymphoma patients. SCHOLAR-5 is an external control cohort designed to act as a comparator to ZUMA-5. Here, we present an updated comparative analysis of ZUMA-5 and SCHOLAR-5, using the 36-month follow-up data and the intent-to-treat population of ZUMA-5. Using propensity-score methods, 127 patients in ZUMA-5 were compared to 129 patients in SCHOLAR-5...
January 24, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38341324/soho-state-of-the-art-updates-and-next-questions-diagnosis-outcomes-and-management-of-prefibrotic-myelofibrosis
#5
REVIEW
Pankit Vachhani, Sanam Loghavi, Prithviraj Bose
Prefibrotic primary myelofibrosis (prefibrotic PMF) is a myeloproliferative neoplasm with distinct characteristics comprising histopathological and clinico-biological parameters. It is classified as a subtype of primary myelofibrosis. In clinical practice, it is essential to correctly distinguish prefibrotic PMF from essential thrombocythemia especially but also overt PMF besides other myeloid neoplasms. Risk stratification and survival outcomes for prefibrotic PMF are worse than that of ET but better than that of overt PMF...
January 21, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38331676/soho-state-of-the-art-updates-and-next-questions-will-car-t-replace-asct-in-ndmm
#6
REVIEW
Eric Jurgens, Saad Z Usmani
The treatment landscape for multiple myeloma (MM) has rapidly evolved over the last 2 decades. The development of triplet and quadruplet regimens including proteasome inhibitors (PI), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies has dramatically extended overall survival. In addition to effective multidrug regimens, autologous stem cell transplant (ASCT) is a cornerstone of management in newly diagnosed multiple myeloma (NDMM). However, despite these combined treatment modalities, curative therapy for MM remains elusive...
January 19, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38378362/venetoclax-and-cobimetinib-in-relapsed-refractory-aml-a-phase-1b-trial
#7
JOURNAL ARTICLE
Marina Y Konopleva, Monique Dail, Naval G Daver, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Kevin R Kelly, Norbert Vey, Sarit Assouline, Gail J Roboz, Stefania Paolini, Daniel A Pollyea, Agostino Tafuri, Joseph M Brandwein, Arnaud Pigneux, Bayard L Powell, Pierre Fenaux, Rebecca L Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Diana Dunshee, Habib Hamidi, Marion G Ott, Wan-Jen Hong, Michael Andreeff
BACKGROUND: Therapies for relapsed/refractory acute myeloid leukemia remain limited and outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or targeted therapies. PATIENTS AND METHODS: This phase 1b trial evaluated venetoclax, a B-cell lymphoma-2 (BCL-2) inhibitor, plus cobimetinib, a MEK1/2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia, ineligible for cytotoxic chemotherapy. Two-dimensional dose-escalation was performed for venetoclax dosed daily, and for cobimetinib dosed on days 1-21 of each 28-day cycle...
January 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38336492/serologic-response-to-vaccine-for-covid-19-in-patients-with-hematologic-malignancy-a-prospective-cohort-study
#8
JOURNAL ARTICLE
Alexandra Hillyer, Anthony Quint, Artin Ghassemian, Nicolette Joh-Carnella, Michael J Knauer, Danny Dawd, Alejandro Lazo-Langner, Joy Mangel, Selay Lam, Husam Abdoh, Anargyros Xenocostas, Uday Deotare, Lalit Saini, Cheryl Foster, Martha Louzada, Jenny Ho, Ian Chin-Yee, Chai W Phua
BACKGROUND: Patients with hematological cancers have increased COVID-19 morbidity and mortality, and these patients show attenuated vaccine responses. This study aimed to characterize the longitudinal humoral immune responses to COVID-19 vaccination in patients with hematological malignancies. PATIENTS AND METHODS: We conducted a prospective cohort study, collecting samples from March 2021 to July 2022, from patients seen at a cancer treatment center in London, Ontario, Canada, who met the following eligibility criteria: age ≥18 years, diagnosed with a hematological malignancy, recipient of a COVID-19 vaccine during the study period, and able to provide informed consent...
January 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38342727/geographic-and-racial-disparities-in-chimeric-antigen-receptor-t-cells-and-bispecific-antibodies-trials-access-for-diffuse-large-b-cell-lymphoma
#9
JOURNAL ARTICLE
Moazzam Shahzad, Muhammad Fareed Khalid, Muhammad Kashif Amin, Ahmad Basharat, Mohammad Ammad-Ud-Din, Robin Park, Iqra Anwar, Muhammad Salman Faisal, Michael Jaglal
BACKGROUND: We investigate the geographical and racial disparities in accessing CAR-T and bispecific antibodies trials for DLBCL. MATERIALS AND METHODS: ClinicalTrials.gov was searched, and 75 trials with at least 1 open site in the US were included. 2020 US Census Bureau data was used to obtain data on race and ethnicity. SPSS version 26 was used for analysis. RESULTS: There were 62 CAR-T and 13 bispecific antibodies trials with 6221 enrolled or expected to enroll patients...
January 17, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38342726/prognostic-impact-of-bone-marrow-fibrosis-and-effects-of-tyrosine-kinase-inhibitors-on-bone-marrow-fibrosis-in-chronic-myeloid-leukemia
#10
JOURNAL ARTICLE
Mehmet Sezgin Pepeler, Mesut Tıglıoglu, Simten Dagdas, Esra Ozhamamcıoglu, Unsal Han, Aynur Albayrak, Mürüvvet Seda Aydın, Gülten Korkmaz, Merve Pamukcuoğlu, Funda Ceran, Murat Albayrak, Gülsüm Ozet
BACKGROUND: Myelofibrosis is reported in around 40% of newly diagnosed chronic myeloid leukemia (CML) patients and have an important role in the pathobiology and prognosis of CML. This retrospective study aimed to evaluate the effects of bone marrow (BM) fibrosis on disease prognosis and the effects of specific tyrosine-kinase inhibitors (TKIs) on BM fibrosis in CML patients. METHODS: The study included 96 patients (>18 years) diagnosed with chronic phase (CP) CML...
January 17, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38278737/a-review-of-the-therapeutic-role-of-bosutinib-in-chronic-myeloid-leukemia
#11
REVIEW
Hagop M Kantarjian, Elias J Jabbour, Jeffrey H Lipton, Fausto Castagnetti, Tim H Brümmendorf
The development of the BCR::ABL1 tyrosine kinase inhibitors (TKIs) has transformed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) from a fatal disease to an often-indolent illness that, when managed effectively, can restore a life expectancy close to that of the normal population. Bosutinib is a second-generation TKI approved for adults with Ph-positive CML in chronic phase, accelerated phase, or blast phase that is resistant or intolerant to prior therapy, and for newly diagnosed Ph-positive chronic phase CML...
January 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38267353/chimeric-antigen-receptor-t-cell-therapy-for-large-b-cell-lymphoma-patients-with-central-nervous-system-involvement-a-systematic-review-and-meta-analysis
#12
REVIEW
Ghada Elgohary, Yang Yang, Mia Gergis, Dongni Yi, Usama Gergis
Chimeric Antigen Receptor T-cell (CAR T-cell) therapy is an effective treatment for relapsed/refractory (R/R) large B cell lymphoma (LBCL). However, patients with central nervous system (CNS) lymphoma were excluded in most of the CAR T-cell therapy trials. This meta-analysis assesses the efficacy with CAR T-cell therapy in LBCL patients with CNS involvement. Two reviewers independently searched PubMed and Cochrane Library to identify all published literature associated with United States Food and Drug Administration approved CAR T-cell therapies for LBCL...
January 12, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38267354/soho-state-of-the-art-updates-and-next-questions-ctls-for-infections-following-stem-cell-transplantation
#13
REVIEW
Ariel Rischall, Amanda Olson
Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important modality in the treatment of acute leukemia and other hematologic disorders. The post-transplant period is associated with prolonged periods of impaired immune function. Delayed T-cell immune reconstitution is correlated with increased risk of viral, bacterial, and fungal infections. This risk increases with high intensity inductions regimens often required for alternative donor sources. Current therapies for prophylaxis and treatment of these infections are limited by poor efficacy and significant toxicity...
January 9, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38195323/soho-state-of-the-art-updates-and-next-questions-next-questions-acute-lymphoblastic-leukemia
#14
REVIEW
Jayastu Senapati, Hagop Kantarjian, Fadi G Haddad, Nicholas J Short, Mary Alma Welch, Nitin Jain, Elias Jabbour
The integration of immune and targeted therapies into the treatment of acute lymphoblastic leukemia (ALL) has significantly improved outcomes, reduced the intensity and duration of chemotherapy, and the reliance on allogeneic stem cell transplantation (SCT). In younger patients with Philadelphia chromosome (Ph)-negative ALL, treatment with Hyper-CVAD and blinatumomab +/- inotuzumab has improved the 3-year overall survival (OS) to above 85%. In older patients, using less intensive chemotherapy (mini-Hyper-CVD) in combination with inotuzumab and blinatumomab has improved the 5-year OS rate to 50%...
January 8, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38220589/an-open-label-phase-i-study-of-metformin-and-nelfinavir-in-combination-with-bortezomib-in-patients-with-relapsed-and-refractory-multiple-myeloma
#15
JOURNAL ARTICLE
Ibrahim Alodhaibi, Sikander Ailawadhi, Gabriel P Burbano, Patrick J O'Brien, Francis K Buadi, Suzanne Hayman, Shaji K Kumar, Wilson I Gonsalves
BACKGROUND: In preclinical models, combining a GLUT4 inhibitor with an oxidative phosphorylation inhibitor shows synergistic therapeutic potential against multiple myeloma (MM). Thus, this study evaluated the safety and tolerability of repurposing metformin, a complex I inhibitor, and nelfinavir, a GLUT4 inhibitor, in combination with bortezomib for the treatment of relapsed/refractory MM that had progressed on all standard of care therapies. MATERIALS AND METHODS: This trial utilized a 3 + 3 dose escalation design with 3 dose levels planned for up to a maximum of 6 (21-day) cycles...
January 6, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38245472/racial-disparities-in-mycosis-fungoides-s%C3%A3-zary-syndrome-a-single-center-observational-study-of-292-patients
#16
JOURNAL ARTICLE
Ashley R Gandham, Shamir Geller, Stephen W Dusza, Thomas S Kupper, Patricia L Myskowski
BACKGROUND: Clinical presentation of Mycosis fungoides/Sézary syndrome (MF/SS) in Black and African American (AA) patients can be heterogeneous with poor survival reported in AA/black patients. In this study, we aim to characterize differences between AA/black and white patients with MF/SS. PATIENTS AND METHODS: A retrospective single-center hospital-based case-control study including 292 MF/SS patients (146 AA/black matched with 146 white patients). We analyzed demographic, clinical and survival differences...
January 3, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38212207/dose-dense-mini-hyper-cvd-inotuzumab-ozogamicin-and-blinatumomab-achieves-rapid-mrd-negativity-in-philadelphia-chromosome-negative-b-cell-acute-lymphoblastic-leukemia
#17
JOURNAL ARTICLE
Nicholas J Short, Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall, Amber Gibson, Nitin Jain, Fadi G Haddad, Lewis F Nasr, Kayleigh R Marx, Caitlin Rausch, J Michael Savoy, Rebecca Garris, Farhad Ravandi, Hagop Kantarjian
BACKGROUND: The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, "dose-dense" administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes. PATIENTS AND METHODS: We performed a retrospective analysis of the safety and efficacy of a dose-dense regimen of mini-hyper-CVD (mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with mini-methotrexate and cytarabine), INO, and blinatumomab in patients with B-cell ALL...
December 30, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38195325/second-treatment-free-remission-attempt-in-patients-with-chronic-myeloid-leukemia
#18
REVIEW
Hiroshi Ureshino, Kazuharu Kamachi, Shinya Kimura
Long-term survival outcomes of patients with chronic myeloid leukemia in the chronic phase are now similar to those of the general population, following the introduction of ABL1 tyrosine kinase inhibitors (TKIs). Approximately 40% to 80% of patients with chronic myeloid leukemia successfully achieved treatment-free remission after the first attempt of TKI discontinuation (TFR1), after achieving a durable deep molecular response. However, the possibility of achieving treatment-free remission after a second attempt of TKI discontinuation (TFR2) remains unclear...
December 29, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38281820/effect-of-tyrosine-kinase-inhibitor-therapy-on-estimated-glomerular-filtration-rate-in-patients-with-chronic-myeloid-leukemia
#19
JOURNAL ARTICLE
Özge Sönmez, Nurgül Özgür Yurttaş, İlker İhtiyaroğlu, Halil Mete Çakır, Zeynep Atlı, Tuğrul Elverdi, Ayşe Salihoğlu, Nurhan Seyahi, Muhlis Cem Ar, Şeniz Öngören, Zafer Başlar, Teoman Soysal, Ahmet Emre Eşkazan
INTRODUCTION: The advent of tyrosine kinase inhibitors (TKIs) was revolutionary in the management of chronic myeloid leukemia (CML). Although TKIs were generally considered to be safe, they can be associated with renal injury. We evaluated the effect of TKIs on renal functions in a cohort of patients with long-term follow-up. MATERIAL AND METHODS: We retrospectively examined patients with chronic phase CML treated with TKIs. We analyzed the estimated glomerular filtration rate (eGFR) of patients from the initiation of TKI to the last follow-up...
December 28, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38262787/epidemiologic-characteristics-treatment-patterns-and-survival-analysis-of-plasmablastic-lymphoma-in-the-united-states-a-seer-and-ncdb-analysis
#20
JOURNAL ARTICLE
Alec R Hansen, Victoria A Vardell, Lindsey A Fitzgerald
BACKGROUND: Plasmablastic Lymphoma (PBL) is a rare aggressive B-cell lymphoma that primarily affects immunocompromised individuals, including those living with HIV. Historically, survival estimates are dismal and range from 8 to 15 months. We aimed to evaluate epidemiologic characteristics, treatment patterns and survival trends on a national scale. PATIENTS AND METHODS: Patients diagnosed with PBL from 2010 to 2020 were identified in the National Cancer Database (NCDB) and in the Surveillance, Epidemiology, and End Results (SEER) program...
December 25, 2023: Clinical Lymphoma, Myeloma & Leukemia
journal
journal
42898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.